Award Data

This Small Business Innovative Research Phase I project is to develop a broad band detection system for air toxicity. Our overall objective is to show that honey bee orientation and locomotor behaviors can be used as reliable and measurable indicators of certain airborne toxicants. Locomotor sufficiency and directional orientation are behaviors that should unambiguously indicate toxicant exposu ...

This project's objective is to develop honey bee colonies as broad band, wide area detectors of airborne toxicants. Phase I focused on identifying behavioral endpoints that assess the locomotor and task solving performance of 'exposed' foragers returning to the hive. Preliminary results indicate that speed of maze navigation and recognition of 'exposed' foragers by entrance guard bees hold prom ...

Many Unites States Army, and other Department of Defense (DoD) sites, are contaminated with a variety of contaminants including highly energetic compounds, such as 2,4,6-trinitrotoluene (TNT), hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX), chlorinated aliphatics (such as trichloroethylene,TCE) and chlorinated aromatics. These compounds often persist in soil or groundwater for extended periods of t ...

Many Unites States Army, and other Department of Defense (DoD) sites, are contaminated with a variety of contaminants including highly energetic compounds, such as 2,4,6-trinitrotoluene (TNT), hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX), chlorinated aliphatics (such as trichloroethylene,TCE) and chlorinated aromatics. These compounds often persist in soil or groundwater for extended periods of t ...

This project develops a conjugate vaccine against Shigella flexneri 2a utilizing cGMP-compatible manufacturing processes. The antigenic component of the vaccine is deacylated-polysaccharide from the bacterial LPS that has an average of one O-antigen repeat unit per polysaccharide molecule. The polysaccharide is deacylated by a biological process, and has a core structure with intact phophosphory ...

There is need for a commercial vaccine against shigellosis because all groups of pathogenic Shigella have acquired resistance to antibiotics. Shigella conjugate vaccines have proven safe and protective in previous clinical trials, but obstacles associated with large-scale manufacturing of these subunit vaccines have apparently hindered commercial development. The present project uses a new and s ...